法国初创公司Ziwig开发的唾液检测工具Ziwig Endotest正在英国和法国用于诊断子宫内膜异位症，声称能够准确识别97%的患者和93%的非患者[1]。该检测费用约为2000美元[1]。法国一项涉及2500名女性的研究预计在今年晚些时候公布结果[1]，英国试验已启动并计划运行三年[1]。
澳大利亚医学专家对这一检测工具在本国的应用前景表示谨慎态度，认为在引入前需要获得更多真实世界数据的支持[1]。澳大利亚每7名18-45岁女性中约有1人患子宫内膜异位症[1]，患者平均需等待6-8年才能获得诊断[1]。澳大利亚妇产科学院（RANZCOG）去年更新了诊疗指南，建议采用经阴道超声而非腹腔镜手术作为首选诊断方法[1]。
专家表示虽然希望有更好、更安全、更便宜、更易获得的检测方法，但该工具作为"一个概率测试，不是真正设计作为诊断测试的"存在局限性[1]。医学界也强调应当尽早对患者症状进行治疗，而不必等待正式确诊[1]。
A saliva-based diagnostic tool for endometriosis developed by French startup Ziwig is currently undergoing trials in the United Kingdom and France, with the company claiming it can accurately identify 97% of patients with the condition and 93% of those without it [1]. The test, called Ziwig Endotest, costs approximately $2,000 USD [1]. A study involving 2,500 women in France is expected to release results later this year, while a UK trial has already begun with an anticipated three-year timeline [1].
Despite these developments, Australian medical experts are expressing caution about adopting the technology without additional real-world evidence [1]. Dr Polyakov characterized the test as "a probability test, not one truly designed as a diagnostic test" [1], highlighting concerns about its clinical application. Dr Druitt acknowledged the need for improved screening methods, stating: "We want better detection methods, ones that are safer, cheaper and more accessible" [1]. Australian guidelines updated by RANZCOG last year now recommend transvaginal ultrasound rather than laparoscopic surgery as the preferred diagnostic approach [1].
The diagnostic burden facing Australian women with endometriosis underscores the relevance of this scrutiny. Approximately one in seven women aged 18–45 in Australia have the condition [1], yet they wait an average of 6–8 years to receive a diagnosis [1]. Experts emphasize the importance of addressing symptoms early rather than delaying treatment pending confirmation [1].